News Article

Dr. Audra Stinchcomb, CSO of AllTranz, Inc., "Developing Transdermal Solutions for a Variety of Neurological Disorders" at the University of Maryland BioPark in Baltimore, MD
Date: Dec 26, 2012
Source: ( click here to go to the source)

Featured firm in this article: AllTranz Inc of Lexington, KY



AllTranz is a specialty pharmaceutical company developing a unique set of dermalNewImage delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz uses dermal product solutions to treat neurological and a variety of other disorders. SNNLive spoke with Dr. Audra Stinchcomb, CSO of AllTranz, Inc. at the University of Maryland BioPark in Baltimore, MD. Dr. Stinchcomb states, "AllTranz is a specialty pharmaceutical company. We make primarily transdermal treatments for pain, and we were founded in 2004." She continues, "we have four products in our development pipeline: one is a THC patch for cancer, chemotherapy, nausea and vomiting and pain treatment and also multiple sclerosis treatment. We also are working on an arthritis gel formulation and an abuse deterrent patch for pain as well… we also partner with other people to help develop their product, so we have both pathways."

She describes the benefit of the THC patch, "It eliminates the medical marijuana political issues by having a real FDA approved dosage form that has fewer side effects than the current oral capsule that's on the market of THC." She continues, "For our transdermal patch we have a [standard] patch like the nicotine patch that you see in the pharmacies. We also have a gel typical to the IcyHot types of gels that are applied for arthritis, so no unusual dosage forms. But we're also getting into the area of what's called microneedles; where you have pain free drug delivery, and you can deliver many, many types of different drugs through the skin that you couldn't do before."

In response to a question about the delivery of large molecules transdermally, Dr. Stinchcomb says, "large molecules are very important; therapeutics in that area are becoming more and more important in the tools that physicians have to use, so our microneedle systems make that ideal for us partnering with all sorts of companies that have their own large molecules that they currently can't deliver through the skin, and the skin is ideal for delivery for once-a-week therapy." For more information about AllTranz, Inc. visit their website. SNNLive welcomes Dr. Audra Stinchcomb, CSO of AllTranz, Inc.